Title : Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

Pub. Date : 2017 May

PMID : 28330649






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peripheral insulin sensitivity in obese hypertensive patients. Valsartan insulin Homo sapiens
2 New use of insulin was 29% lower in patients receiving sacubitril/valsartan (114 [7%] patients) compared with patients receiving enalapril (153 [10%]; hazard ratio 0 71, 95% CI 0 56-0 90, p=0 0052). Valsartan insulin Homo sapiens